GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant increase in short interest in June. As of June 15th, there was short interest totalling 109,000 shares, an increase of 142.8% from the May 31st total of 44,900 shares. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.4% of the company’s stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent quarter. Institutional investors own 6.09% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright raised their price objective on GeoVax Labs from $8.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, June 18th.

GeoVax Labs Stock Down 10.3 %

Shares of GOVX stock opened at $3.19 on Friday. GeoVax Labs has a 1-year low of $1.09 and a 1-year high of $10.24. The stock’s 50-day moving average is $1.76 and its 200 day moving average is $2.72.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. On average, analysts forecast that GeoVax Labs will post -7.41 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.